Piper Sandler lowered the firm’s price target on Century Therapeutics to $9 from $10 and keeps an Overweight rating on the shares. Century acquired Clade for preclinical alpha-beta CAR-iT including CLDE-308 and CLDE-361 for $35M in cash and stock, solidifying Century’s leading position in iPSC-derived cell therapies, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IPSC:
- Century Therapeutics Executes Strategic Acquisition and Equity Sales
- Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics
- Century Therapeutics announces strategic pipeline expansion
- Century Therapeutics: Data from iPSC-derived cell therapy presented at AACR
- Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting
